BioNTech completes acquisition of CureVac with 86.75% of shares tendered.
ByAinvest
Thursday, Dec 18, 2025 4:49 am ET1min read
BNTX--
CVAC--
BioNTech has completed its exchange offer to acquire CureVac, with approximately 86.75% of CureVac shares tendered. BioNTech expects to complete the compulsory acquisition of remaining CureVac shares in January 2026. CureVac will continue to operate under its existing processes, while BioNTech will analyze the future organizational and portfolio setup. The acquisition complements BioNTech's capabilities in mRNA design, delivery, and manufacturing.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet